Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Arcus Biosciences, Inc. before investing.

In this article, we go over a few key elements for understanding Arcus Biosciences, Inc.’s stock price such as:

• Arcus Biosciences, Inc.’s current stock price and volume
• Why Arcus Biosciences, Inc.’s stock price changed recently
• Upgrades and downgrades for RCUS from analysts
• RCUS’s stock price momentum as measured by its relative strength

About Arcus Biosciences, Inc. (RCUS)

Before we jump into Arcus Biosciences, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Want to learn more about Arcus Biosciences, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Arcus Biosciences, Inc..

What Caused Arcus Biosciences, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 29, 2026, there were 0 analysts who downgraded Arcus Biosciences, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Arcus Biosciences, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Arcus Biosciences, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Arcus Biosciences, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Arcus Biosciences, Inc. (RCUS) by visiting AAII Stock Evaluator.

Relative Price Strength of Arcus Biosciences, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 29, 2026, Arcus Biosciences, Inc. has a weighted four-quarter relative price strength of 23.25%, which translates to a Momentum Score of 92 and is considered to be Very Strong.

Want to learn more about how Arcus Biosciences, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Arcus Biosciences, Inc. Stock Price: Bottom Line

As of June 1, 2026, Arcus Biosciences, Inc.’s stock price is $24.990, which is down 1.38% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Arcus Biosciences, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.